May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Macular pigment density subject to different stages of age–related maculopathy
Author Affiliations & Notes
  • C. Jahn
    Augenklinik, University of Leipzig, Leipzig, Germany
  • H. Wüstemeyer
    Augenklinik, University of Essen, Essen, Germany
  • C. Brinkmann
    Augenklinik, University of Leipzig, Leipzig, Germany
  • S. Trautmann
    Augenklinik, University of Leipzig, Leipzig, Germany
  • A. Mößner
    Augenklinik, University of Leipzig, Leipzig, Germany
  • U. Schnurrbusch
    Augenklinik, University of Leipzig, Leipzig, Germany
  • S. Wolf
    Augenklinik, University of Leipzig, Leipzig, Germany
  • Footnotes
    Commercial Relationships  C. Jahn, None; H. Wüstemeyer, None; C. Brinkmann, None; S. Trautmann, None; A. Mößner, None; U. Schnurrbusch, None; S. Wolf, None.
  • Footnotes
    Support  DFG WO 478/11–1
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 2968. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. Jahn, H. Wüstemeyer, C. Brinkmann, S. Trautmann, A. Mößner, U. Schnurrbusch, S. Wolf; Macular pigment density subject to different stages of age–related maculopathy . Invest. Ophthalmol. Vis. Sci. 2004;45(13):2968.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Macular pigment (MP) is attempt to have a protective role in the development and progression of age–related maculopathy (ARM). We present results of measurements of macular pigment density (MPD) in patients with ARM at different stages with a modified confocal scanning laser ophthalmoscope (HRA, Heidelberg Engineering, Heidelberg, Germany). Methods: Patients with ARM were recruited for this study. The severity of ARM was categorized into 3 groups according to the Rotterdam Study classification (stage 1–3). The staging depended upon the size and shape of drusen, presence of pigmentary abnormalities and atrophic or neovascular AMD changes. Macular pigment density maps were calculated from autofluorescence images recorded with a modified HRA at 488 nm and 514 nm. MPD was quantified from the MPD maps within 2 degrees around the center of the fovea. As controls a group of 155 healthy subjects were examined. Results: We included 237 patients with ARM into this study. There were significant differences between MPD in ARM patients as compared with healthy controls (ARM: MPD = 0,195±0,075 D.U.; controls: MPD = 0,214±0,077 D.U.; p < 0.05). Subgroup analysis revealed significant differences between patients with ARM stage 1 (0,186±0,074 D.U.,; n=109) and patients with ARM stage 3 (0,191±0,079 D.U.; n=65) and healthy subjects. No differences were found for patients with ARM stage 2 (0,213±0,068D.U.; n=63) Conclusions: Our study showed significant differences of MPD between healthy subjects and the patients with minimal (stage 1) and severe (stage 3) ARM pathologies. Further longitudinal studies are necessary to compare the incidence of AMD in eyes with high and low MPD in order to provide a definite evidence of the influence of MPD on the progression of AMD.

Keywords: age–related macular degeneration • macular pigment 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×